126832-81-3

Basic information

• Product Name: 1-PYRIDIN-4-YLPIPERIDIN-4-ONE
• Synonyms: 1-PYRIDIN-4-YLPIPERIDIN-4-ONE;2,3,5,6-TETRAHYDRO-[1,4']BIPYRIDINYL-4-ONE;1-(4-Pyridinyl)-4-piperidinone
• CAS NO: 126832-81-3
• Molecular Formula: C₁₀H₁₂N₂O
• Molecular Weight: 176.21508
• Mol File: 126832-81-3.mol

Chemical Properties

• Boiling Point: 340.797 °C at 760 mmHg
• Flash Point: 159.908 °C
• Appearance: /
• Density: 1.164 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 10.54±0.10(Predicted)
• CAS DataBase Reference: 1-PYRIDIN-4-YLPIPERIDIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PYRIDIN-4-YLPIPERIDIN-4-ONE(126832-81-3)
• EPA Substance Registry System: 1-PYRIDIN-4-YLPIPERIDIN-4-ONE(126832-81-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 126832-81-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Pyridin-4-ylpiperidin-4-one is used as a key intermediate for the synthesis of various biologically active compounds, particularly in the development of pharmaceutical drugs. Its structural features enable the creation of complex molecules with diverse therapeutic applications, contributing to the advancement of new medications.
Used in Agrochemical Industry:
1-Pyridin-4-ylpiperidin-4-one is also utilized as a building block in the synthesis of agrochemicals, such as pesticides and herbicides. Its chemical versatility allows for the development of novel compounds with improved efficacy and selectivity in agricultural applications.
Used in Materials Science:
Due to its unique chemical structure and reactivity, 1-Pyridin-4-ylpiperidin-4-one may have potential applications in materials science. It could be used in the development of new materials with specific properties, such as improved conductivity or stability, for use in various industrial processes.
Used in Organic Synthesis:
1-Pyridin-4-ylpiperidin-4-one is used as a versatile intermediate in organic synthesis, allowing for the construction of complex molecules with a wide range of applications. Its presence in the synthesis process can lead to the creation of new compounds with potential uses in various industries.

Upstream product

• 19524-06-2 4-bromopyridine hydrochloride 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 7379-35-3 4-chlorpyridine hydrochloride 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 74129-11-6 4-bromopyridine hydrobromide salt 
• 1120-87-2 4-bromopyridin 
• 166954-75-2 8-(pyridin-4-yl)-1,4-dioxa-8-azaspiro[4.5]decane 

Downstream Products

• 1235971-79-5 4-(4-benzyl-piperazin-1-yl)-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl 
• 1235971-67-1 4-(4-phenyl-piperazin-1-yl)-3,4,5,6-tetrahydro-2H-[1,4']-bipyridinyl 
• 1365135-35-8 (3R)-3-[(2-chlorobenzoyl)amino]-N-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-2,3-dihydro-1H-indene-5-carboxylic acid amide 

Relevant articles and documents

Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.

Substituted Benzamide Compounds

Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

PIPERIDIN-4-YLPIPERAZINE COMPOUNDS FOR THE TREATMENT OF HCV INFECTION

The invention relates to new piperazine-pieridine compounds having anti-viral activity and particularly anti-HCV activity. The invention further relates to pharmaceutical compositions comprising compounds according to the invention.

An improved synthesis of N-aryl and N-heteroaryl substituted piperidones

An efficient Pd(0)-catalyzed protocol for the rapid and efficient preparation of N-aryl and N-heteroaryl substituted piperidones is described. The two step syntheses proceed with an overall yield of 50-70% using X-Phos as optimal ligand for the Pd(0)-cata

Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring

A series of novel 2,7-disubstituted tetrahydroisoquinoline derivatives were designed and synthesized. Among these derivatives, compounds 1 and 2 exhibited potent inhibitory activity against factor Xa (FXa) and good selectivity with respect to other serine

Amidine compounds

A compound of the formula [I] wherein R1, R2and R3are the same or different and each is hydrogen atom, wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof. The compound of the presen

Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds

The present invention concerns new amino alcohol derivatives, a process for their production as well as pharmaceutical preparations and reagents which contain these substances. The invention concerns pharmaceutical agents of the general formula I in which A denotes hydrogen, a group NR1R2, a group NR1(CH2)pNR3R4, a group (C═NH)NH2 or a pyridinyl residue, B and D are the same or different and each denotes a bond, a C1 to C6 alkylene residue or a group NR5—C2 to C6-alkylene, C denotes piperidinediyl or piperazinediyl, W and X are the same or different and each denotes a bond or a carbonyl group, Y and Z are the same or different and each denotes a saturated or unsaturated hydrocarbon residue with 7 to 24 carbon atoms, R1 to R5are the same or different and each represents hydrogen or a C1 to C6 alkyl residue, m is an integer 0, 1 or 2 and if m equals 2 C can also independently of one another be piperidinediyl or piperazinediyl, n and o are the same or different and each denotes the integers 2, 3 or 4 and p denotes an integer from 2 to 6 as well as physiologically tolerated salts thereof, provided that hydrazine derivatives are not included and that m cannot be 0 if A denotes hydrogen or a group (C═NH)NH2 and B and D being the same or different represent a bond or an alkylene residue.

ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF

Novel acylhydrazine derivatives exhibiting an inhibitory activity against activated blood coagulation factor X, which are compounds of general formula (I)or salts thereof, wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; R1and R2are each hydrogen or optionally substituted hydrocarbyl, or alternatively R1and R2or the substituent of X1and R2may be united to form an optionally substituted ring; X1and X2are each free valency, optionally substituted alkylene, or optionally substituted imino; D is oxygen or sulfur; A is -N(R3)-Y- or -N=Y-, R3is hydrogen, optionally substituted hydrocarbyl, or acyl; Y is an optionally substituted chain hydrocarbon group or an optionally substituted cyclic group; and Z is (1) optionally substituted amino, (2) optionally substituted imidoyl, or (3) an optionally substituted nitrogenous heterocycle group.

Sulfonamide derivatives, processes for producing the same and utilization thereof

The present invention is to provide a compound or a salt thereof represented by the formula: wherein R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, X′ is an optionally substituted alkylene chain, Y is an optionally substituted divalent cyclic group, X is a chemical bond or an optionally substituted alkylene chain, and Z is (1) an optionally substituted amino group, (2) an optionally substituted imidoyl group or (3) an optionally substituted nitrogen-containing heterocyclic group, or a pro-drug thereof, which have activated coagulation factor X inhibitory activity and which are useful as anti-coagulants.

Oxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds

The present invention concerns new oxazolidinone derivatives, processes for their production as well as pharmaceutical agents containing these substances. The present invention concerns compounds of the general formula I STR1 in which the symbols have the meanings as listed in the claims.